Aryl hydrocarbon‐estrogen alpha receptor‐dependent expression of miR‐206, miR‐27b, and miR‐133a suppress cell proliferation and migration in MCF‐7 cells

Mobini, Keivan; Tamaddon, Gholamhossein; Fardid, Reza; Keshavarzi, Majid; Mohammadi-Bardbori, Afshin

doi:10.1002/jbt.22304

Cited by 16 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In esophageal cancer, miR-133a could targeted EGFR, and thus promote cell apoptosis and radio-sensitivity via downregulating the MEK/ERK pathway 5 . MiR-133a also served a tumor suppressor by modulating the ERalpha and AhR signaling pathways in breast cancer cell line MCF-7 18 . MiR-133a increased apoptosis and inhibited proliferation in colorectal cancer by regulating the RFFL expression, inducing a G0/G1-phase arrest and activating p53/p21 signaling 19 .…”

Section: Mir-133a In Cell Proliferation and Apoptosismentioning

confidence: 99%

Emerging roles of MiR-133a in human cancers

Hua¹,

Xu²,

Li³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

MicroRNAs (miRNAs) can post-transcriptionally regulate the expression of cancer-relevant genes via binding to the 3'-untranslated region (3'-UTR) of the target mRNAs. MiR-133a, as a miRNA, participate in tumorigenesis, progression, autophagy and drug-resistance in various malignancies. Based on the recent insights, we discuss the functions of miR-133a in physiological and pathological processes and its potential effects on cancer diagnosis, prognosis and therapy.

show abstract

Section: Mir-133a In Cell Proliferation and Apoptosismentioning

confidence: 99%

Emerging roles of MiR-133a in human cancers

Hua¹,

Xu²,

Li³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Finally, AhR has been shown to prevent tumor development through the regulation of several tumor suppressor miRNAs in breast cancer [61], prostate cancer [62], and malignant tumors of the endometrium [63].…”

Section: Ahr As a Tumor Suppressormentioning

confidence: 99%

AhR and Cancer: from Gene Profiling to Targeted Therapy

Paris

Tardif

Galibert

et al. 2020

Preprint

View full text Add to dashboard Cite

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that has been shown to be an essential regulator of a broad spectrum of biological activities required for maintaining the body's vital functions. AhR also plays a critical role in tumorigenesis. Its role in cancer is complex, encompassing both pro- and anti-tumorigenic activities. Its level of expression and activity are specific to each tumor and patient, increasing the difficulty of understanding the activating or inhibiting roles of AhR ligands. We explored the role of AhR in tumor cell lines and patients using genomic data sets and discuss the extent to which AhR can be considered as a therapeutic target.

show abstract

“…Since miRNAs are able to target numerous different transcripts, it is not surprising that miR-27b-3p was reported to exert seemingly conflicting roles in different tumor cells. MiR-27b-3p was reported to inhibit proliferation and metastasis in ER-positive breast cancer ( 13 , 14 ). The tumor suppressive function of miR-27b-3p in ER-positive breast cancer may result from hypermethylation in the miR-27b-3p promoter region, affecting the targets and downstream signaling pathways of miR-27b-3p ( 13 , 24 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, several papers reported conflicting roles of miR-27b-3p in breast cancer. In luminal-subtype breast cancer (ER-positive), miR-27b-3p was reported to be negatively regulated by ER to inhibit proliferation of breast cancer cells and high miR-27b-3p level indicated good survival ( 13 , 14 ). Thus, the role of miR-27b-3p in breast cancer appears to be dependent on the molecular subtype of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Introduction: The role and underlying mechanisms of miR-27b-3p in triple-negative breast cancer (TNBC) remains unclear. Methods: miR-27b-3p expression level was evaluated in 99 TNBC patients with a median follow-up time of 133 months. The biological functions of miR-27b-3p by targeting PPARG were assessed by luciferase reporter assay, CCK-8 assay, Transwell assay, wound healing assay, western blot analysis and xenograft models. Results: High level of miR-27b-3p expression was found to confer poor prognosis in TNBC patients. MiR-27b-3p overexpression increased TNBC cell proliferation, migration, invasion, and metastasis. Our data suggested peroxisome proliferator-activated receptor gamma (PPARG) was a target of miR-27b-3p. The capacity of miR-27b-3p to induce TNBC progression and metastasis depended on its inhibition of the PPARG expression. Furthermore, restoring PPARG expression reversed the effect of miR-27b-3p overexpression. Mechanistically, miR-27b-3p regulated metastasis-related pathways through PPARG by promoting epithelial–mesenchymal transition. By suppressing PPARG, miR-27b-3p could also activate transcription factors Snail and NF-κB, thereby promoting metastasis. Conclusions: miR-27b-3p promotes TNBC progression and metastasis by inhibiting PPARG. MiR-27b-3p may be a potential prognostic marker of TNBC, and PPARG may be a potential molecular therapeutic target of TNBC.

show abstract

Aryl hydrocarbon‐estrogen alpha receptor‐dependent expression of miR‐206, miR‐27b, and miR‐133a suppress cell proliferation and migration in MCF‐7 cells

Cited by 16 publications

References 42 publications

Emerging roles of MiR-133a in human cancers

Emerging roles of MiR-133a in human cancers

AhR and Cancer: from Gene Profiling to Targeted Therapy

MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer

Contact Info

Product

Resources

About